Matching articles for "botulinum toxin"
Drugs for Prevention of Migraine
The Medical Letter on Drugs and Therapeutics • September 28, 2026; (Issue 1764)
Indications for preventive treatment of migraine include
frequent or severe attacks, contraindications to or toxicity with
acute treatments, and patient preference. Drugs for acute
treatment of migraine were...
Indications for preventive treatment of migraine include
frequent or severe attacks, contraindications to or toxicity with
acute treatments, and patient preference. Drugs for acute
treatment of migraine were reviewed in a previous issue.
Comparison Table: Some Drugs for Migraine Prevention (online only)
The Medical Letter on Drugs and Therapeutics • September 28, 2026; (Issue 1764)
...
View the Comparison Table: Some Drugs for Migraine Prevention
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • October 5, 2020; (Issue 1608)
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine headache pain in most patients without
vascular disease. Early treatment of pain when it is
still mild to moderate in intensity improves headache
response and reduces the risk of recurrence.
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019; (Issue 1572)
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.
Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
Qbrexza (Dermira), a premoistened cloth containing
the long-acting anticholinergic drug glycopyrronium,
has been approved by the FDA for once-daily topical
treatment of excessive underarm sweating...
Qbrexza (Dermira), a premoistened cloth containing
the long-acting anticholinergic drug glycopyrronium,
has been approved by the FDA for once-daily topical
treatment of excessive underarm sweating (primary
axillary hyperhidrosis) in patients ≥9 years old.
Glycopyrronium bromide (glycopyrrolate) has been
available for years in parenteral, inhalation, and oral
formulations for treatment of multiple conditions.
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • November 5, 2018; (Issue 1559)
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in...
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and galcanezumab
are the second and third subcutaneously
injected monoclonal antibodies that target the CGRP
pathway to be approved by the FDA for this indication;
erenumab-aooe (Aimovig), which targets the CGRP
receptor, was the first.
Erenumab (Aimovig) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • June 18, 2018; (Issue 1549)
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive...
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive treatment
of migraine in adults. It is the first drug in its class to
be approved by the FDA.
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • February 12, 2018; (Issue 1540)
Nonopioid drugs can be used in the treatment of many
nociceptive and neuropathic pain conditions. Use of
opioids for pain will be reviewed in a future...
Nonopioid drugs can be used in the treatment of many
nociceptive and neuropathic pain conditions. Use of
opioids for pain will be reviewed in a future issue.
Valbenazine (Ingrezza) for Tardive Dyskinesia
The Medical Letter on Drugs and Therapeutics • May 22, 2017; (Issue 1521)
The FDA has approved valbenazine (Ingrezza –
Neurocrine Biosciences), a vesicular monoamine
transporter 2 (VMAT2) inhibitor, for treatment of
tardive dyskinesia in adults. It is the first drug to
be...
The FDA has approved valbenazine (Ingrezza –
Neurocrine Biosciences), a vesicular monoamine
transporter 2 (VMAT2) inhibitor, for treatment of
tardive dyskinesia in adults. It is the first drug to
be approved in the US for this indication; two other
VMAT2 inhibitors, tetrabenazine (Xenazine, and
generics) and deutetrabenazine (Austedo), were
approved earlier for treatment of chorea associated
with Huntington's disease.
Exablate Neuro for Essential Tremor
The Medical Letter on Drugs and Therapeutics • March 27, 2017; (Issue 1517)
The FDA has approved use of Exablate Neuro (Insightec)
for unilateral thalamotomy to treat medication-refractory
essential tremor in patients ≥22 years old.
Exablate Neuro uses magnetic...
The FDA has approved use of Exablate Neuro (Insightec)
for unilateral thalamotomy to treat medication-refractory
essential tremor in patients ≥22 years old.
Exablate Neuro uses magnetic resonance-guided
focused ultrasound (MRgFUS) to create lesions in the
ventral intermediate nucleus of the thalamus. MRgFUS
is also approved in the US for treatment of uterine
fibroids and for pain palliation of bone metastases.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use of
a triptan early in an attack when pain is still mild to
moderate in intensity improves headache response
and reduces recurrence rates.
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • December 1, 2013; (Issue 136)
Treatment of migraine in the emergency department,
which may involve use of intravenous drugs, is not
discussed...
Treatment of migraine in the emergency department,
which may involve use of intravenous drugs, is not
discussed here.
Botox for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • April 15, 2013; (Issue 1414)
The FDA has recently approved intradetrusor injection
of onabotulinumtoxinA (Botox – Allergan) for treatment
of overactive bladder in patients who cannot tolerate or
have an inadequate response to...
The FDA has recently approved intradetrusor injection
of onabotulinumtoxinA (Botox – Allergan) for treatment
of overactive bladder in patients who cannot tolerate or
have an inadequate response to anticholinergic therapy.
Botox is also approved by the FDA for use in
detrusor overactivity associated with a neurologic condition
such as multiple sclerosis or spinal cord injury,
and for chronic migraine, upper limb spasticity, axillary
hyperhidrosis, cervical dystonia, blepharospasm, strabismus,
and cosmetic reduction of wrinkles.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2013; (Issue 128)
Pain can be acute or chronic. The two major types of
chronic pain are nociceptive pain and neuropathic
pain. Nociceptive pain can be treated with nonopioid
analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. The two major types of
chronic pain are nociceptive pain and neuropathic
pain. Nociceptive pain can be treated with nonopioid
analgesics or opioids. Neuropathic pain is less responsive
to opioids and is often treated with adjuvant drugs
such as antidepressants and antiepileptics. Combining
different types of analgesics may provide an additive
analgesic effect without increasing adverse effects.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 1, 2011; (Issue 102)
Drugs for treatment of migraine are listed in Table 2
on page 9. Drugs for prevention of migraine are listed
in Table 3 on page 10. Treatment of migraine in the
emergency room, which may involve use of...
Drugs for treatment of migraine are listed in Table 2
on page 9. Drugs for prevention of migraine are listed
in Table 3 on page 10. Treatment of migraine in the
emergency room, which may involve use of intravenous
drugs, is not included here.
Botulinum Toxin for Chronic Migraine
The Medical Letter on Drugs and Therapeutics • January 24, 2011; (Issue 1356)
The FDA has approved injection of onabotulinumtoxinA
(Botox – Allergan) for prevention of
headaches in adult patients with chronic migraine (≥15
headache days/month for ≥3 months). It is the...
The FDA has approved injection of onabotulinumtoxinA
(Botox – Allergan) for prevention of
headaches in adult patients with chronic migraine (≥15
headache days/month for ≥3 months). It is the first
drug approved for treatment of this indication. Botox is
also FDA-approved for treatment of upper limb spasticity,
axillary hyperhidrosis, cervical dystonia, blepharospasm
and strabismus, and for cosmetic
reduction of wrinkles.
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
The Medical Letter on Drugs and Therapeutics • November 15, 2010; (Issue 1351)
The FDA has approved incobotulinumtoxinA (Xeomin –
Merz) for treatment of cervical dystonia and blepharospasm
in adults. It has been commercially available
in Germany since 2005. Several formulations...
The FDA has approved incobotulinumtoxinA (Xeomin –
Merz) for treatment of cervical dystonia and blepharospasm
in adults. It has been commercially available
in Germany since 2005. Several formulations of
botulinum toxin type A (Botox; Dysport) and type B
(Myobloc) are already marketed for treatment of cervical
dystonia. Botox is also approved for treatment of blepharospasm.
Drugs for Pain
The Medical Letter on Drugs and Therapeutics • April 1, 2010; (Issue 92)
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less...
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • March 1, 2008; (Issue 67)
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve...
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Exenatide (Byetta) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • June 6, 2005; (Issue 1210)
Exenatide injection (Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2...
Exenatide injection (Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin (Glucophage, and others), a sulfonylurea, such as glyburide (DiaBeta, and others), or both. Exenatide is not indicated for use with insulin.
Botulinum Toxin (Botox) for Axillary Hyperhidrosis
The Medical Letter on Drugs and Therapeutics • September 13, 2004; (Issue 1191)
Botulinum toxin type A (Botox - Allergan) has been approved by the FDA for treatment of severe underarm sweating ("primary axillary hyperhidrosis"). Injected into the skin, botulinum toxin decreases sweating by...
Botulinum toxin type A (Botox - Allergan) has been approved by the FDA for treatment of severe underarm sweating ("primary axillary hyperhidrosis"). Injected into the skin, botulinum toxin decreases sweating by causing chemical denervation of the sweat gland.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • September 1, 2004; (Issue 25)
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004;...
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004; 63:520). Drugs for prevention of migraine are listed in the table on page 65. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Cosmetic Use of Botulinum Toxin
The Medical Letter on Drugs and Therapeutics • July 16, 1999; (Issue 1057)
Botulinum toxin type A has been marketed in the USA since 1989 for treatment of strabismus and blepharospasm and has also been used to treat cervical dystonia and some other muscular...
Botulinum toxin type A has been marketed in the USA since 1989 for treatment of strabismus and blepharospasm and has also been used to treat cervical dystonia and some other muscular disorders.
Botulinum Toxin for Ocular Muscle Disorders
The Medical Letter on Drugs and Therapeutics • November 2, 1990; (Issue 830)
Botulinum toxin Type A (Oculinum - Allergan), used investigationally for many years to treat ocular muscle disorders (Medical Letter, 29:101, 1987), has now been approved by the US Food and Drug...
Botulinum toxin Type A (Oculinum - Allergan), used investigationally for many years to treat ocular muscle disorders (Medical Letter, 29:101, 1987), has now been approved by the US Food and Drug Administration for intramuscular treatment of strabismus and blepharospasm in patients more than 12 years old.